Amgen (AMGN) Q1 'Disappointing' - Nomura
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/9/2026
- S&P 500 falls as AI worries hit software makers
- Brent crude hits six-week high near $97 as Houthi strike targets Saudi Aramco
- Qualcomm stock surges 9.5% on Amazon AI deal & 25M share warrant
- Energy stocks rise premarket as oil prices climb on Middle East supply fears
- Novartis shares plunge 10% as failed drug trial clouds growth outlook
- Harry and Meghan surprised by King Charles' letter on their status
- Citi initiates UiPath coverage with Buy rating and $23 target
- S&P 500 falls as AI worries hit software makers
- WestPark Capital Starts Akebia Therapeutics (AKBA) at Buy
- After an 18% summer selloff in chip stocks, Citi asks what comes next
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
Amgen (AMGN) Has the Best Pipeline in Biotech, Piper Jaffray Says
April 25, 2014 7:38 AM EDTPiper Jaffray analyst Joshua E. Schimmer, MD reiterated an Overweight rating and $143 price target on Amgen (NASDAQ: AMGN) Friday saying a deep dive analysis into AMGN's migraine program suggests they are likely to... More
Amgen, Inc. (AMGN) Misses Q1 EPS by 7c
April 22, 2014 4:48 PM EDTAmgen, Inc. (NASDAQ: AMGN) reported Q1 EPS of $1.87, $0.07 worse than the analyst estimate of $1.94. Revenue for the quarter came in at $4.52 billion versus the consensus estimate of $4.76 billion.
For earnings history and earnings-related data on Amgen, Inc. (AMGN) click here.
... More